



ECONOMIC IMPACT DERIVED FROM PARTICIPATION ON ANTIRETROVIRAL THERAPY CLINICAL TRIALS IN A THIRD-LEVEL HOSPITAL

S.GUTIÉRREZ PALOMO, G.MIRALLES ANDREU, N.OLCINA FORNER, O.GUILLÉN MARTÍNEZ, C.MATOSOS CHIRIVELLA, A.NAVARRO RUIZ
Hospital General Universitario De Elche, Pharmacy, Elche, Spain
farmacia_elx@gva.es

BACKGROUND AND IMPORTANCE

- ✓ Antiretroviral therapy (ART) cost: important expense in the annual Hospital Pharmacy Service (PS) investment
- ✓ Clinical trials (CTs) for ART development: high percentage of the CTs carried out in a PS
- ✓ Opportunity for the hospital in terms of cost savings for these medications

AIM AND OBJECTIVES


- ✓ To analyse the avoided cost of ART medications because of patient participation in CTs

MATERIAL AND METHODS


- ✓ Retrospective observational study that includes all patients who were participating in CTs against human immunodeficiency virus (HIV) treated with ART



From January 2021
to March 2023



- ✓ Number of patients
- ✓ Investigational drugs
- ✓ Visits and dispensations



- ✓ Orion Clinic®
- ✓ Fundanet®



**Avoided cost
calculated**


=

Treatment cost that the patient would have
received if they had not participated in the CT

-

CT treatment cost
paid by the hospital

RESULTS



- ✓ **89 patients included**
- ✓ Mean age: 44 ± 12 years old
- ✓ Sex: 77 (87%) men




- ✓ **13 CTs analyzed**
- ✓ Mean participation time: 16 months
- ✓ Clinical visits: 1,075 (12/patient)
- ✓ Dispensations: 2,997 (26/patient)



- ✓ Intramuscular ART : 3 CTs
- ✓ Oral ART : 10 CTs
- ✓ Average of investigational drugs : 2/CTs

Treatment if patient not included in CT	%
Dolutegravir/Abacavir/Lamivudine	32.6
Bictegravir/Emtricitabine/Tenofovir Alafenamide	14.6
Dolutegravir/Lamivudine	14.6
Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide	13.5



**Avoided cost
calculated** = 734,432 € - 12,636 € = **721,796 €**

HOSPITAL SAVINGS

333,136.60 € / year

8,110.10 € / patient

3,743.10 € / year * patient

CONCLUSION AND RELEVANCE

- ✓ Patients' inclusion in HIV CTs considerably reduces the pharmaceutical expenses related with ART medications since investigational drugs are provided free of charge by the sponsor
- ✓ CTs represent important economic savings for hospital, contribute to the Spanish Health System sustainability and allow access to new therapies